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the largest increase (95%) observed in LatinAmerica. By 2002,many (n9) countries
had reached absolute prevalence rates  30%. The high prevalence of AD as re-
ported by ISAAC was confirmed in the remaining literature, especially in a popu-
lation of young children and infants, with rates of up to 60%. The reported inci-
dence rates for a similar population were as high as approximately 10%.
CONCLUSIONS: AD is one of the most prevalent disease conditions in childhood,
with an increasing trend in most parts of the world.
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OBJECTIVES: The objective was to examine the factors that influence dental care,
dental expenditures, and dental insurance among children (2-17) in the US. Dental
caries are the most prevalent childhood chronic disease. Lack of dental care in
childhood can lead to poor health outcomes and decreased quality of life.
METHODS: The Medical Expenditure Panel Survey data (2008), descriptive statis-
tics, linear regression, and logistic regression were used to perform a cross sec-
tional retrospective analysis. Covariates included race, residence, insurance status,
and family income. RESULTS: Mean dental expenditures per child in 2008 was
$1,246. Half (52%) of children had dental insurance, and half (54%) used preventa-
tive dental services. Children that utilized preventative services had annual mean
dental expenditures ($559) that were significantly lower than children that did not
utilize preventative services ($2,092). Logistic regression analysis indicated that
children without caries were more likely (OR: 2.43 [2.42-2.44]) to have preventative
care than children with caries. Higher income and dental insurance were positive
predictors of preventative dental care. Those with dental insurance had higher
mean annual expenditures ($1,579) compared with those uninsured ($975), indi-
cating that dental insurance increases dental resource use. Predicting factors for
dental insurance were lack of caries, preventative service utilization, higher in-
come, residence in theNortheast orMidwest, Asian descent, andwhite race. Linear
regression showed that dental expenditures were lower among those without
dental insurance, with preventative services, residing in a non-metropolitan
statistical area, black race, Hispanic ethnicity, and residing outside the
northeast. CONCLUSIONS: The data indicate that dental insurance is not the only
barrier to children’s dental care. Certain racial and ethnic groups and lower familial
income are negative predictors for dental care. Preventative services lower dental
expenditures and prevent caries. Therefore the return on investment for preven-
tative services is positive. Health reform should enact policies encouraging preven-
tative dental services.
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OBJECTIVES: To systematically compare the safety of latanoprost versus timolol
through meta-analysis of randomized controlled trials (RCTs) in open angle glau-
coma (OAG) or ocular hypertension (OH). METHODS: Medline and Cochrane Cen-
tral Register of Controlled Trials (CCTR) were searched for RCTs published post
2000, assessing head to head comparison of latanoprost vs. timolol in OAG or OH.
Studies were assessed for inclusion/exclusion based on a prespecified protocol.
Two reviewers undertook data extraction independently. Any disagreement was
resolved by a third reviewer. A customized spreadsheet was used to extract the
relevant outcomes, including the study duration, sample size, number of patients
with local and systemic side effects and the proportion of withdrawals due to
adverse events. RESULTS: Four RCTs enrolling 1688 patients met the inclusion
criteria out of the 289 studies identified. Latanoprost was associated with an in-
creased incidence of hyperemia (risk ratio (RR)  2.7, 95% CI  1.37 to 5.28), iris
pigmentation (RR  10.81, 95% CI  1.37 to 85.47) and pruritus (RR  3.05, 95% CI 
1.06 to 8.73) compared to timolol (Level I evidence). Also, one RCT (Level II evidence)
reported that latanoprost was associated with increased incidences of eyelash
changes (risk difference (RD) 0.23, 95% CI 0.16 to 0.29; number needed to harm
(NNH) 4, 95%CI 3 to 6). Other AEs commonly observedwith both the treatments
were blepharitis, cataract, dry eye, eye irritation, eye pain and keratitis. There was
no statistically significant difference for withdrawals due to AEs across both the
treatments (RD 0.02, 95% CI0.02 to 0.05). CONCLUSIONS: Timolol displayed a
better safety profile than latanoprost for adverse events including hyperemia, iris
pigmentation and pruritus. However, long term safety could not be assessed as few
included studies evaluated patients beyond six months.
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OBJECTIVES: To assess the economic burden from vision loss on the health care
system in Taiwan. METHODS: This is a retrospective matched cohort study, with
study population retrieved from the National Health Insurance Research Database
between 01/01/2000 and 12/31/2008. Based on the ICD-9-CM codes, cases initially
diagnosed with moderate vision loss (369.6-369.9), severe vision loss (369.1-369.4),
or blindness (369.0-369.08) were identified. Each case was matched to a randomly
selected control with normal vision by age ( 1 year) and gender. Each control was
assigned the same index date, the initial diagnosis date of vision loss, as the cor-
responding case. For each pair, the annual medical costs were calculated during
the one year after index date. All medical costs were adjusted to 2010 New Taiwan
dollars (NT$, US$1 
 NT$30). A generalized linear model with gamma distribution
and log-link was used to estimate the differences in post-index annual increased
costs while adjusting for baseline characteristics and pre-index logged costs. Boot-
strapping techniquewas used to generate 95% confidence interval (CI). RESULTS:A
total of 2,233, 283, and 350 patients with moderate vision loss, severe vision loss,
and blindness were identified, respectively. Patients with moderate vision loss,
severe vision loss, and blindness had NT$13,888 (CI 8,564-19,236), NT$23,768 (CI
7,764-42,379) andNT$75,461 (CI 56,123-94,685) higher annualmedical costs as com-
pared with their matched controls. Inpatient services (62.3%) constituted the larg-
est component of total medical costs for blindness, followed by outpatient services
(26.8%) and emergence care (4.3%). Similar patterns were observed for moderate
and severe vision loss. CONCLUSIONS: Consistent with the Western world, signif-
icantly higher medical costs are associated with vision loss in Taiwan. The addi-
tional costs seem to be related to the extent of the vision loss, with blindness
incurring the highest costs, followed by severe vision loss and then moderate vi-
sion loss.
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OBJECTIVES: A systematic review of the literature was performed to gather the
economic evidence related to atopic dermatitis (AD) in children.METHODS: OVID
MEDLINE® and EMBASE™ were explored by two reviewers for a combined search
with terms related to economics and quality of life in a paediatric population, for
the period 1996-2010. This abstract reports the results of the economic review. Two
reviewers browsed abstracts, retrieved the suitable articles, separated them into
cost of illness (COI) and economic evaluations including cost comparisons (CC),
cost-effectiveness (CEA) and cost-utility analyses (CUA), and summarized key
points. A third person acted as overall reviewer and adjudicator in case of
disagreement. RESULTS: From an initial search yielding 704 references, 16 articles
were included in the review, 7 COI and 9 economic evaluations, including 2 CC, 3
CUA and 1 CEA of treatment with immunomodulators, 1 CC of corticosteroids and
1CEAof homeopathy aswell as 1 CEA on a partially hydrolysed infant formula used
in prevention. The investigation period span from 1995 to 2010. Four studies were
performed in the UK, 3 in the US, 2 in Australia, 2 in Canada, 2 in Germany, 1 in
France, 1 in Italy and 1 covered 10 European countries. The range of yearly mean
cost for treating AD is very wide and increases according to severity. Themain cost
drivers seem to be consultations, hospitalizations, emollients and prescription
medications, as well as time loss for parents. CONCLUSIONS: Given its high prev-
alence, AD carries a substantial economic burden on such stakeholders as the
national healthcare systems and the family of the affected children. In light of
these findings, an approach based on prevention rather than treatment may have
a greater economic impact. In turn, further research is warranted on the potential
economic benefit from interventions aimed at prevention.
PSS9
COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR
CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING
Waycaster C
Healthpoint Ltd., Fort Worth, TX, USA
OBJECTIVES: To assess the cost-effectiveness of collagenase enzymatic debride-
ment relative to hydrogel autolytic debridement for pressure ulcers in a long-term
care setting. METHODS: A 2-stage Markov model was used to determine the ex-
pected costs of wound debridement between collagenase and hydrogel dressings
for pressure ulcers in a long-term care setting. The two Markov states used in the
analysis were a necrotic non-viable wound bed and a debrided viable wound bed.
Outcome data used in the analysis were taken from a randomized clinical trial that
directly compared collagenase and hydrogel dressings in a long-term care nursing
facility. The primary outcome in the clinical trial was the proportion of patients
achieving a viable, granulated wound bed at 42 days. Transition probabilities for
the Markov states were estimated from the clinical trial. Resource utilization was
based on the wound care treatment regimen used in the clinical trial. Resource
utilization costs were derived from standard cost references and medical supply
wholesalers. All costs are expressed in 2010 U.S. dollars. The payer perspectivewas
taken in the economic analysis and no cost discounting was performed due to the
short time horizon of the study. One-way and probabilistic sensitivity analyses
were performed to establish the robustness of the economic results. RESULTS: The
clinical trial established that 85% of the collagenase subjects versus 29% of the
hydrogel subjects achieved a debrided wound bed at the 42-day assessment.
The economic analysis indicated that 42 days after initiating treatment the cost-
effectiveness ratio for collagenase was $85 per debrided day compared to $184 per
debrided day using a hydrogel dressing. One-way and probabilistic sensitivity anal-
yses indicated that the results were robust within the modeled parameters.
CONCLUSIONS: Results indicate that collagenase ointment is cost effective for the
debridement of pressure ulcers compared to autolysis with a hydrogel dressing.
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